The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C Patients Receiving a Personalized Treatment Program

Open access


Objective To investigate the effects of individualised treatment with peginterferon alpha-2a (40 kD) plus ribavirin in Chinese patients with CHC.

Methods Total of 297 consecutive Chinese patients were enrolled, including 250 naïve cases and 47 cases who were previously treated. Treatment duration was determined according to viral genotypes, prior treatment history and viral responses at week 4, 12 and 24.

Results Totally, 235 patients (79.1%) completed treatment and 186 (87.3%) achieved SVR. And 219 out of 289 (75.8%) patients achieved HCV RNA negative at week 4 (RVR) and 259 of 276 (93.8%) at week 12. Among the 164 patients with RVR who completed follow-up, 158 (96.3%) achieved SVR. Patients with RVR had lower baseline viral loads than patients without RVR (P = 0.034). The positive predictive value (PPV) of RVR for SVR was 90.7% (OR 2.10 vs. non-RVR, 95% CI: 0.50 - 8.7). Similar outcomes were observed among patients with HCV undetectable at week 12.

Conclusions Complete viral suppression by week 4 is associated with a high rate of treatment success in treatment naïve and experienced patients receiving individualized CHC therapy.

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.

2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.

3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.

4. Nguyen-Khac E, Capron D, Castelain S, Francois C, Braillon A. Personalized therapy for chronic viral hepatitis C in the naïve patient: How can we optimize treatment duration as a function of viral genotype? Eur J Intern Med 2007; 18:510-515.

5. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.

6. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41:275-279.

7. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44:1675-1684.

8. Nunez M, Marino A, Miralles C, Berdun MA, Sola J, Hernandez-Burruezo JJ, et al. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/ HCV-coinfected patients. J Acquir Immune Defic Syndr 2007; 45:439-444.

9. Zekri AR, El-Din HM, Bahnassy AA, Khaled MM, Omar A, Fouad I, et al. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. Virol J 2007; 4:16.

10. Powis J, Peltekian KM, Lee SS, Sherman M, Bain VG, Cooper C, et al. Exploring differences in response to treatment with peginterferon alpha 2a (40 kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 2008; 15:52-57.

11. Rodriguez-Torres M, Rios-Bedoya CF, Ortiz-Lasanta G, Purcell-Arevalo D, Marxuach-Cuetara A, Jimenez-Rivera J. Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks. J Med Virol 2008; 80:1576-1580.

12. Tural C, Galeras JA, Planas R, Coll S, Sirera G, Gimenez D, et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther 2008; 13:1047-1055.

13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009; 461:399-401.

14. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di CGG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138:116-122.

15. Rumi MG, Aghemo A, Prati GM, D’Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138:108-115.

16. Moriyama M, Matsumura H, Nirei K, Arakawa Y, Yamagami H, Ogawa M, et al. Factors influencing treatment efficacy of 24-week combination therapy with interferon alpha-2b plus ribavirin for chronic hepatitis C. Dig Dis Sci 2007; 52:2418-2426.

17. Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di BAM, Morgan TR, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008; 48:1033-1043.

18. Ladero JM. Optimizing dosage and duration therapy for chronic hepatitis C ”difficult-to-treat patients”. Ann Hepatol 2008; 7:392-394.

19. Reddy KR, Shiffman ML, Rodriguez-Torres M, Abdurakhmanov D, Bakulin I, Silva GF, et al. Standard versus higher induction doses of peginterferon alfa-2a (40 kD) and/or higher ribavirin (RBV) in HCV G1 patients with high viral load and body weight >85 kg. Final results of the PROGRESS study. Hepatology 2009; 50:330A-331A.

20. Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. A Benelux randomized trial in 300 patients. J Hepatol 2004; 40:689-695.

21. Berg T, von WM, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1:comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.

22. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131:451-460.

23. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46:1688-1694.

24. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150:528-540.

25. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43:425-433.

26. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47:1260-1269.

27. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103:1131-1135.

28. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81:452-458.

29. de Segadas-Soares JA, Villela-Nogueira CA, Perez RM, Nabuco LC, Brandao-Mello CE, Coelho HS. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis C patients treated with peginterferon-alpha2b and ribavirin? J Clin Gastroenterol 2009; 43:362-366.

30. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13 Suppl 1:9-16.

31. Marcellin P, Jensen D, Hadziyannis S, Ferenci P. Differentiation of early virological response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40 kD) (Pegasys) and ribavirin (Copegus) [abstract no. 1308]. Hepatology 2007; 46: 818.

32. Reau N, Satoskar R, Te H, DeVoss A, Elsen C, Reddy G, et al. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol 2011; 106:452-458.

33. Shiffman M, Pappas SBB, Godofsky E, Nelson D, Harley H, Diago M, et al. Utility of virological response at weeks 4 and 12 in the prediction of SVR rates in genotype 2/3 patients treated with peginterferon alfa-2a patients (40 kD) plus ribavirin: findings from ACCELERATE [abstract 340]. Hepatology 2006; 44 (Suppl 1):316A.

34. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 2010;138:503-512, 512.e1.

35. Napoli N, Giannelli G, Antonaci A, Antonaci S. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. J Viral Hepat 2008; 15:300-304.

36. Tsubota A, Satoh K, Aizawa M, Takamatsu S, Namiki Y, Ohkusa T, et al. Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study. World J Gastroenterol 2008; 14:7220-7224.

37. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-458.

38. Nanxiong S, Xiaofeng F, Shacocai D. The study on hepatitis C genotype based on simmond’s classification by using restriction endonuclease method. Jiangsu Yi Yao (Chin) 1999; 25:481-483.

39. Wang C, Pflugheber J, Sumpter R Jr, Sodora DL, Hui D, Sen GC, et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 2003; 77:3898-3912.

40. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008; 89:1-47.

41. Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005; 19:17-26.

42. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001; 55:255-281.

43. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49:S103-S111.

44. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53:1504-1508.

45. Swain MG, Lai MY, Shiffman ML, Cooksley WGE, Abergel A, Lin A, et al. Durable sustained virological response after treatment with peginterferon alfa-2a (Pegasys) alone or in combination with ribavirin (Copegus): 5-year follow-up and the criteria of a cure [abstract no.1]. J Hepatol 2007;46:S3.

46. Afdhal NH, Levine R, Brown R, Freilich B, O’Brien M, Brass C. Colchichine versus peg-interferon alfa-2b long term therapy: results of the 4 year copilot trial. J Hepatol 2008; 48 (Suppl 2):S4.

47. Di BAM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med Overseas Ed 2008; 359:2429-2441.

48. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (New York, N.Y.) 1998; 282:103-107.

49. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:1438-1447.

50. Layden JE, Layden TJ, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002; 9:340-345.

51. Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007; 133:1132-1143.

52. Reau N, DeVoss A, Elsen C, He H, Satoskar R, Mohanty S, et al. Evaluation of early null-response (ENR) as a predictor of nonresponse to PEG RBV in patients with HCV. Oral presentation at the 50th annual meeting of the American Association for the Study of the Liver Disease, San Francisco 2008. Available online at . Last accessed 14.01.2011.

53. Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148:120-127.

54. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36:S145-S151.

55. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ ribavirin therapy. Hepatology (Baltimore, Md.) 2006; 43:954-960.

56. Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, et al. Efficacy and safety of peginterferon alfa-2a (40 kD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51:388-397.

57. Poordad F, Kambilli C. Predictability of response: positive and negative predictive values of rapid and early virologic responses to peginterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C [abstract 305]. Hepatology 2007; 46:375A.

58. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134.

59. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617.

60. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-836.

61. Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, et al. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat 2008; 15:641-645.

62. Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009; 49:358-363.

63. Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009; 50:1045-1055.

64. Jacobson IM, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky MS, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007; 46:982-990.

65. Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flatdose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology 2007; 46:971-981.

66. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358.

67. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102:2181-2188.

68. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189:964-970.

Journal Information


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 187 181 10
PDF Downloads 51 49 4